Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.

Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Drüeke TB, Massy ZA.

Nephrol Dial Transplant. 2012 Feb;27(2):505-13. doi: 10.1093/ndt/gfr254. Epub 2011 Jun 24.

PMID:
21705467
2.

Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice.

Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov IG, Vanholder R, Lacour B, Drüeke TB, Massy ZA.

Circulation. 2005 Nov 1;112(18):2875-82.

3.

Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice.

Nikolov IG, Joki N, Galmiche A, Nguyen-Khoa T, Guerrera IC, Guillonneau F, Ivanovski O, Phan O, Maizel J, Marçon F, Benchitrit J, Lucas A, Edelman A, Lacour B, Drüeke TB, Massy ZA.

Atherosclerosis. 2013 Jul;229(1):42-51. doi: 10.1016/j.atherosclerosis.2013.02.041. Epub 2013 Apr 22.

PMID:
23672878
4.

Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.

De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E.

Kidney Int. 2013 Jun;83(6):1109-17. doi: 10.1038/ki.2013.34. Epub 2013 Mar 13.

5.

Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.

Phan O, Maillard M, Malluche HH, Stehle JC, Funk F, Burnier M.

Biomed Res Int. 2015;2015:515606. doi: 10.1155/2015/515606. Epub 2015 Jun 29.

6.

Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice.

Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drüeke TB, Muntzel MS.

J Am Soc Nephrol. 2005 Jan;16(1):109-16. Epub 2004 Nov 24.

7.

Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure.

Phan O, Ivanovski O, Nikolov IG, Joki N, Maizel J, Louvet L, Chasseraud M, Nguyen-Khoa T, Lacour B, Drüeke TB, Massy ZA.

Nephrol Dial Transplant. 2008 Jan;23(1):82-90. Epub 2007 Oct 31.

PMID:
17977878
8.

Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.

Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E.

Kidney Int. 2003 Nov;64(5):1653-61.

9.

Peritoneal delivery of sodium pyrophosphate blocks the progression of pre-existing vascular calcification in uremic apolipoprotein-E knockout mice.

de Oliveira RB, Louvet L, Riser BL, Barreto FC, Benchitrit J, Rezg R, Poirot S, Jorgetti V, Drüeke TB, Massy ZA.

Calcif Tissue Int. 2015 Aug;97(2):179-92. doi: 10.1007/s00223-015-0020-7. Epub 2015 Jun 19.

PMID:
26087714
10.

High phosphate feeding induced arterial medial calcification in uremic rats: roles of Lanthanum carbonate on protecting vasculature.

Yu C, Chen B, Zhao T, Wang R, Akhtar J, Wang H, Zhang H.

Life Sci. 2013 Oct 17;93(17):646-53. doi: 10.1016/j.lfs.2013.08.013. Epub 2013 Sep 6.

PMID:
24012609
11.

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

Sprague SM.

Curr Med Res Opin. 2007 Dec;23(12):3167-75. Review. Erratum in: Curr Med Res Opin. 2008 Mar;24(3):708.

PMID:
17991307
12.

The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice.

Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drüeke TB, Massy ZA.

Atherosclerosis. 2009 Jul;205(1):55-62. doi: 10.1016/j.atherosclerosis.2008.10.043. Epub 2008 Nov 18.

PMID:
19118829
13.

Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.

Behets GJ, Dams G, Damment SJ, Martin P, De Broe ME, D'Haese PC.

Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F61-7. doi: 10.1152/ajprenal.00219.2013. Epub 2013 Nov 6. Erratum in: Am J Physiol Renal Physiol. 2014 Mar 1;306(5):F568.

14.

Effects of efficient phosphate binding on bone in chronic renal failure rats.

Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC.

Ren Fail. 2005;27(4):475-84.

PMID:
16060138
15.

The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.

Liu L, Wang Y, Chen H, Zhu X, Zhou L, Yang Y.

Ren Fail. 2014 Sep;36(8):1244-52. doi: 10.3109/0886022X.2014.938544. Epub 2014 Jul 14. Review.

PMID:
25019348
16.

Emerging drugs for hyperphosphatemia.

Bellinghieri G, Santoro D, Savica V.

Expert Opin Emerg Drugs. 2007 Sep;12(3):355-65. Review.

PMID:
17874966
17.

Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.

Yamada S, Tatsumoto N, Tokumoto M, Noguchi H, Ooboshi H, Kitazono T, Tsuruya K.

Calcif Tissue Int. 2015 Apr;96(4):347-58. doi: 10.1007/s00223-014-9929-5. Epub 2014 Dec 16.

PMID:
25511229
18.

Atherosclerosis and vascular calcification in uraemia - a new experimental model.

Ivanovski O, Nikolov IG, Drueke BT, Massy AZ.

Prilozi. 2007 Dec;28(2):11-24. Review.

PMID:
18356775
19.

Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.

Cozzolino M, Brancaccio D.

Expert Opin Emerg Drugs. 2007 Sep;12(3):341-3.

PMID:
17874964

Supplemental Content

Support Center